Making the Impossible Possible

At UroGen, making the impossible possible for patients with urological cancers is a reality, not just an idea.

Welcome to UroGen®

We are a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases.

We combine innovative technology with new perspectives on traditional therapy to bring new ideas to light and help patients fight cancer without major surgery—and without the fear of it coming right back—making what seemed impossible, possible.

Patient image of woman on a beach

Our people make us who we are

At UroGen, we're passionate about making a difference for patients with urologic diseases—and we know true progress can only be made when diverse minds come together for this common goal.

Learn more about UroGen >
Patient image of woman on a beach

Our people make us who we are

At UroGen, we're passionate about making a difference for patients with urologic diseases—and we know true progress can only be made when diverse minds come together for this common goal.

Learn more about UroGen >

An industry-leading uro-oncology pipeline

Our investigational product candidates put us on the cutting edge of advancing treatments for urologic and uro-oncological conditions, including non-muscle invasive bladder cancer.

Explore our pipeline >
Hand holding a light bulb
Hand holding a light bulb

An industry-leading uro-oncology pipeline

Our investigational product candidates put us on the cutting edge of advancing treatments for urologic and uro-oncological conditions, including non-muscle invasive bladder cancer.

Explore our pipeline >
Man and woman in a lab

Our trailblazing therapies

JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.

See our products and solutions >
Man and woman in a lab

Our trailblazing therapies

JELMYTO® (mitomycin) for pyelocalyceal solution is the first FDA-approved treatment using our novel RTGel technology. JELMYTO is the first and only treatment of its kind and received breakthrough approval in April 2020.

See our products and solutions >
October 05, 2021
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
September 23, 2021
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 13, 2021
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
October 5, 2021
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
September 23, 2021
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 13, 2021
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting